Please review the criteria for Acceptance of Posters and the instructions below regarding preparation of Poster Session Abstracts before completing the online forms.

1. All abstracts must be submitted electronically via the submission form below. Submissions are not considered complete until all required forms from all authors have been received.
2. Type the title of the abstract in CAPITAL LETTERS. The title should not exceed 10 words.
3. Text within the Poster Abstract box must include the title as well as authors' and presenters' names as this is the text that is reproduced for publication. Do not exceed 300 words.
4. Spell out complete names of all authors on the "AUTHORS:" line in the Poster Abstract box. Do not use initials alone. List city and state of origin. For abstracts submitted by multiple authors from one city, list the city and state once after all authors’ names have been listed.
5. Indicate the name(s) of the presenter(s) on the "PRESENTED BY:" line in the Poster Abstract box.
6. Type single­s spaced within the abstract box. Double space only between paragraphs.
7. The abstract should be informative and detailed. It must contain the following: an introduction and objective; methods; results obtained; and conclusion(s). It is not acceptable merely to state that the results will be discussed.
8. Avoid excessive abbreviations in abstract. Abbreviations may be used only after the word has been written out once in full in the abstract.
9. All abstract presentations and the question and­ answer period will be in English.

There are three categories that will be judged: Content, Presentation, and Visual Aesthetics. Under content, the judges will be looking at: Introduction and Objectives, Methods Used, Results Obtained, and Conclusion(s).

 

Other criteria include: Validity of study or topic area to clinical medicine or medical direction in PALTC continuum (e.g., geriatric and non-geriatric SNFs, home care, hospice, and subacute care); Clarity of description and depth of detail used to report each of the content areas listed above; Practical application; Innovation in thought or approach; and Best use of illustrations and tables, including clarity and ease of reading and arrangement in sequence according to their reference in the text.

Poster Presenter Disclosure Declaration Policy

In order to ensure the continued success and reputation for integrity of our education programs. MMDA - The Mid-Atlantic Society for Post-Acute and Long-Term Care Medicine has adopted this full disclosure policy.

It is not only proper, but likely, that faculty will have relationships with industry and corporations. On occasion, situations may arise in which an individual faculty member has an outside interest that could be perceived as a conflict of interest. There is no attempt to preclude anyone from participating in any continuing medical education activity. It is our responsibility to disclose to the participants in that activity the nature of the relationship so those who may form their own judgments about the presentation.

Required Disclosures: As a potential poster presenter, PALTmed and MMDA require you to disclose all financial relationships that you have had in the past 24 months with ineligible companies – any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. There is no minimum financial threshold; we ask that you disclose all financial relationships with ineligible companies, regardless of the amount. You should disclose all financial relationships regardless of the potential relevance of each relationship to the education provided. For specific examples of ineligible companies visit ACCME.org. 

Duty to Disclose

Each poster presenter member shall disclose any real or perceived relationships that are pertinent to the subject matter and could potentially be interpreted as biasing a presentation. In addition, poster presenters must disclose "off­ label " uses of substances or products included in the presentation that are not approved in the United States and/or the status of substances or products that are being investigated for such use. Relationships that must be disclosed include, but are not limited to:

• Service as a paid or non­paid consultant or employee;
• Significant personal holdings (by the faculty member and/or his/her immediate family) in any commercial entity that provides financial support to MMDA, or products or services related to the subject matter;
• Receipt of financial support from a commercial firm or other source (consultant, research, educational grant, speakers bureau, honoraria, royalties, commissions, etc.);
• Research or institutional support.

Financial Relationship Disclosure Statement

ALL authors must complete and submit either Section A online, or if Section B is required, the entire Disclosure Statement form must be downloaded, completed and submitted, in its entirety.

It is the policy of MMDA – The Mid-Atlantic Society for Post-Acute and Long-Term Care Medicine to ensure balance, independence, objectivity, and scientific rigor in all of its sponsored educational programs. It remains for the audience to determine whether outside interests may reflect a possible bias in either the exposition or the conclusion(s) presented. Participant agrees to accept no payment for participation in this poster activity from any source.

This form must be completed and returned by each presenter/co­presenter.

Activity Title: MMDA's 32nd Annual Conference

Date: Nov. 8, 2025

Please complete and sign Sections A and C, or Sections B and C, below:

SECTION A

I have no financial conflict of interest or other relationship with a commercial entity in relation to this presentation. My presentation does not include discussion of "off­label" substance(s)/product(s) not approved in the United States for use under discussion or of substance(s)/product(s) that are being investigated for such use.

Please complete and sign Sections A and C, or Sections B and C, below:

SECTION B: Financial and Scientific Disclosures

In order to maintain scientific balance and integrity in presentations, all disclosures will be included in on­site program materials.

SECTION C: Scientific Integrity and Commercial Support

By signature at the end of this disclosure declaration, I attest that I have carefully complied with ACCME Standards for Commercial Support and MMDA's policies regarding content and presentation of educational material, specifically, that my presentation will (please check each item delineated below to indicate your agreement):